Physician profile
Sonam Puri
NPI 1346675915
$42,135.27
in general payments reported to CMS, 2019-2025
18 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $1,370 · 2022: $4,999 · 2023: $8,183 · 2024: $13K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Honoraria: $9,535 · Travel and Lodging: $2,102 · Food and Beverage: $838 · Education: $73.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,068.50 |
| Honoraria | $9,535.00 |
| Travel and Lodging | $2,101.83 |
| Food and Beverage | $837.52 |
| Education | $73.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $6,429.41 | 2023-2024 | Optune Lua (Novottf-200t) |
| E.R. Squibb & Sons, L.L.C. | $5,723.98 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $4,999.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,552.50 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $3,541.74 | 2020-2025 | Enhertu, Imfinzi |
| Janssen Biotech, INC. | $3,340.00 | 2025 | Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $3,150.00 | 2024 | Alunbrig |
| Amgen INC. | $2,744.00 | 2025 | Imdelltra (Amg757) |
| Immunitybio, INC. | $2,500.00 | 2025 | |
| G1 Therapeutics, INC. | $2,477.19 | 2023 | Cosela |
| Pfizer INC. | $1,800.00 | 2023 | |
| Janssen Scientific Affairs, LLC | $1,200.00 | 2024 | |
| Daiichi Sankyo INC. | $514.50 | 2025 | |
| Genentech USA, INC. | $149.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.96 | 2023 | Rybrevant |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonam Puri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.